Pharmaceuticals
'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
MELBOURNE, Australia, Sept. 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON[1] trial have been published in The Lancet Oncology, reporting that Telix's first-in-class investigational PET[2] agent,...
2024-09-11 06:46
1422
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024
GAITHERSBURG, Md., Sept. 10, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...
2024-09-10 20:00
3025
ICP DAS-BMP Reveals Advanced Engineering TPUs at Medtec China 2024
HSINCHU, Sept. 10, 2024 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based medical TPU (thermoplastic polyurethane) manufacturer and supplier, is excited to announce its participation in Medtec China 2024. The 18th edition of this exhibition will be held fromSeptember 25-27, 202...
2024-09-10 09:30
1590
Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation
SAN FRANCISCO and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...
2024-09-10 08:00
1858
Seegene Expands mpox RUO Product Lineups with Enhanced Detection Assays for Clade 1
* Introduces Novaplex™ MPXV/OPXV plus Assay (RUO) that is designed to detect Clade I, which has higher transmission and mortality rates than Clade II * Adheres to the WHO issued target product profiles and provides accurate detection of viral strains * Offers healthcare professionals with ...
2024-09-09 22:15
1941
Sirsram Medical announces NMPA approval for DAXXIFY®
Marking the introduction of the world's first and only peptide-powered botulinum toxin product to Mainland China HONG KONG, Sept. 9, 2024 /PRNewswire/ -- Sisram Medical (1696.HK), a global leading innovator and provider of holistic medical aesthetic solutions announced today that the National M...
2024-09-09 19:46
1348
A. Menarini Diagnostics and Nucleix announce a strategic partnership for a non-invasive bladder cancer test in Europe
Under the commercial agreement, A. Menarini Diagnostics will assume exclusive marketing of the non-invasive Bladder EpiCheck® test in Europe in the months ahead, providing patients and clinicians with a urine test to detect and monitor recurrence of bladder cancer and upper tract urothelial carci...
2024-09-09 15:00
1077
Three Study Results Abstracts From Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) At 2024 ESMO Released Today
CHENGDU, China, Sept. 9, 2024 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2024 will be held inBarcelona, Spain from September 13 to 17, 2024. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd（"Kelun-Biotech", 6990.HK）will present the following results of its anti-TROP...
2024-09-09 14:27
1161
ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress
ROCKVILLE, Md. and SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malignancies, today announced that it will present the latest c...
2024-09-09 08:25
1559
Sciwind Biosciences Announces Oral Presentations at the European Association for the Study of Diabetes 60th Annual Meeting (EASD 2024)
HANGZHOU, China and SAN FRANCISCO, Sept. 6, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that the company will present positive results from a ...
2024-09-06 10:10
1913
Chugai Pharma Taiwan wins Social Empowerment and Green Leadership Categories at the Asia Responsible Enterprise Awards 2024
SINGAPORE, Sept. 4, 2024 /PRNewswire/ -- The Asia Responsible Enterprise Awards (AREA) 2024 honored Chugai Pharma Taiwan as an outstanding business leader that champions sustainable and responsible business practices. Presented by leading regional NGO Enterprise Asia, the AREA ceremony was held i...
2024-09-05 10:47
1461
Veeva Vault CRM Suite to Unlock Greater Customer Centricity with Launch of Service Center
Expanded suite to unify sales, marketing, medical and service through a
connected software and data foundation
SINGAPORE, Sept. 5, 2024 /PRNewswire/ -- Veeva Systems
2024-09-05 09:00
1667
TraceLink's Magnum Release of its Opus Platform Will Revolutionize Supply Chain Management by Enabling All Businesses to Digitalize their End-to-End Supply Networks
With real-time information from all supply chain partners, Supply Chain Managers can reduce inventory and stock-out while improving service levels and lead times BOSTON, Sept. 4, 2024 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the ...
2024-09-04 22:00
1549
LakeShore Biopharma Announces Leadership Transitions
GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...
2024-09-04 20:00
1385
Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma
SAN FRANCISCO and SUZHOU, China, Sept. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2024-09-04 08:00
3946
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
MELBOURNE, Australia, Sept. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company's IPAX-1 Phase I study has been published inNeuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 thera...
2024-09-04 06:57
1825
Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate Syndromic PCR Diagnostic Assays
- Nature Awards MDx Impact Grants in partnership with Seegene extends commitment to external innovation. - Global research teams invited to submit proposals to develop new tests for human infectious diseases. Application deadline:December 2, 2024. - Nature Awards to lead the application and eva...
2024-09-02 21:00
2138
Frost & Sullivan Released Report: "BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies"
SHANGHAI, Sept. 2, 2024 /PRNewswire/ -- Frost & Sullivan released a report, titled "BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies". The report explores a global CDMO leading the "The Fourth Revolutionary Wave of Biologics Manufacturing" and pioneering...
2024-09-02 17:20
1607
Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024
SAN FRANCISCO and SUZHOU, China, Sept. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2024-09-02 08:23
3283
Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI®(encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation
* European approval is based on results from the Phase II PHAROS trial, which showed a meaningful clinical benefit to BRAFV600E mutated advanced NSCLC patients with an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients.[1-3] The safety profil...
2024-08-30 20:44
4124
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 301 media titles]
2024-11-21 10:30Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8676
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5434
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
4839